PHVS
$26.00-0.13 (-0.50%)
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Recent News
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap
Recent price performance and trigger context Pharvaris (PHVS) has recently drawn investor attention after shares closed at $25.09, with the stock showing a negative 1 day move, a small decline over the past week, and gains over the past month and past 3 months. See our latest analysis for Pharvaris. Looking beyond the recent pullback, Pharvaris has a 30 day share price return of 4.15%, a 90 day share price return of 18.80%, and a 1 year total shareholder return of 36.66%. This suggests...
What Does Wall Street Think About Pharvaris N.V. (PHVS)?
Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pharvaris N.V. (NASDAQ:PHVS) also received a rating update from Oppenheimer on December 4, with the company reaffirming […]
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.